<DOC>
	<DOC>NCT00108108</DOC>
	<brief_summary>The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with chronic lymphocytic leukemia who are relapsed after receiving prior treatment.</brief_summary>
	<brief_title>Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Clinical diagnosis of CLL requiring treatment Refractory or relapsed disease Prior treatment with fludarabine Male or Female &gt;18 years of age Treatment with rituximab within 90 days and alemtuzumab or any monoclonal antibody within 6 months. Clinically significant cardiac dysfunction or other significant organ dysfunction Additional eligibility criteria apply that will be reviewed with potential study subjects at the site.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Lymphocytic Leukemia</keyword>
</DOC>